Researchers at the U.K.'s University of Bristol developed mathematical models to assess the use of biomarkers for detecting glioblastomas (GBMs), and their potential for improvement.
The research could lead to a simple point-of-care blood test for brain tumor diagnosis.
When the researchers matched the models with experimental data, they learned that lowering the current threshold for the prospective biomarker Glial fibrillary acidic protein could detect GBMs earlier.
The team also applied computational modeling to investigate the effect of tumor characteristics and patient differences on detection and improvement strategies.
Said Bristol's Johanna Blee, "These mathematical models could be used to examine and compare new biomarkers and tests for brain tumors as they emerge."
From University of Bristol News (U.K.)
View Full Article
Abstracts Copyright © 2022 SmithBucklin, Washington, DC, USA
No entries found